Echothiophate-Induced Structural Alterations in the Anterior Chamber Angle of the Cynomolgus Monkey

Total Page:16

File Type:pdf, Size:1020Kb

Echothiophate-Induced Structural Alterations in the Anterior Chamber Angle of the Cynomolgus Monkey Echothiophate-induced structural alterations in the anterior chamber angle of the cynomolgus monkey Elke Liitjen-Drecoll and Paul L. Kaufman Four cynomolgus monkeys were treated topically twice daily in one eye with echothiophate iodide (PI) doses of 63, 75, or 250 fjig per treatment for 7.7 weeks to 7 months. The opposite eyes of two monkeys received a control solution (diluent). The anterior ocular segments of all six eyes were studied by light and transmission electron microscopy during treatment. In the Pl-treated eyes, the cribriform and outer corneoscleral meshwork were unusually dense. The trabecular meshwork was collapsed and the lamellae showed thickened basement membranes and thickened sheaths of elastic-like material. Most endothelial cells were enlarged and activated. Some contained many glycogen particles; others showed evidence of degeneration. The crib- riform meshwork contained much more extracellular fine fibrillar material than normal, and the endothelium of the inner wall of Schlemm's canal was damaged. The Pi-contracted ciliary muscle had a more rectangular shape than normally contracted muscles, and the inner edge extended so far anteriorly that in some areas it overlapped and occluded the trabecular meshwork. The muscle cells appeared damaged, and their basement membranes were thickened. The nonpigmented epithelial cells of the ciliary processes showed signs of degenera- tion, and within the pars plana some contained large, weakly osmiophilic inclusions. The basement membrane of the ciliary epithelium was thickened everywhere. The stromal vessels of the pars plana were dilated, and signs of inflammation were present. The sphincter iridis was damaged and there were iridocorneal adhesions. The 5 month diluent-treated eye demonstrated mild structural abnormalities in the meshwork. Key words: angle-closure glaucoma, anterior chamber angle, canal of Schlemm, cholinesterase inhibitors, ciliary muscle, ciliary processes, echothiophate, iris, monkey eye, trabecular meshwork Long-acting cholinesterase (ChE) inhibitors From the Department of Anatomy, University of are applied topically to the human eye for the Erlangen-Niirnberg, Erlangen, West Germany; the treatment of some cases of glaucoma. These Department of Medical Pharmacology, University of drugs lower intraocular pressure (IOP) at Uppsala, Uppsala, Sweden; and the Department of least initially by increasing the facility of Ophthalmology, University of Wisconsin Medical aqueous humor outflow. Although ChE in- School, Madison, Wise. Supported by grants from the Deutsche Forschungsge- hibitors may provide long-term lowering of meinschaft, Bad Godesberg (Ro 81/14, to Prof. J. W. IOP in many cases, some eyes eventually be- Rohen) and the National Institutes of Health (EY00231, come refractory to these drugs.1 A possible IF03 EY55678, 5 SOI RR05435). reason for this is decreased sensitivity of Submitted for publication Aug. 15, 1978. outflow facility to cholinomimetic com- Reprint requests: Dr. Elke Liitjen-Drecoll, Anatom- 2 isches Institut der Universitat Erlangen-Niirnberg, pounds, presumably due to acetylcholine- 8520 Erlangen, Krankenhausstrasse 9, West Germany. induced cholinergic subsensitivity of the 918 0146-0404/79/090918 + 12$01.20/0 © 1979 Assoc. for Res. in Vis. and Ophthal., Inc. Downloaded from iovs.arvojournals.org on 09/26/2021 Volume 18 Number 9 Echothiophate-induced angle changes 919 A IP 4, -20 © © © © © -40 PV PV AV AV g r -30 c < 300 ^ ® PI 2.5 % m -12 m z ©DILUENT H -20^ NO CATARACT »1 ® DILUENT O NO CATARACT 10 5 > © PI 0.5% CYNO 110 CYNO 225 35 DAYS DAYS 200- © © © © © © •40 C PV PV PV PV PV iA A A >- I 50- 1 1 1 I 30 < O © PI 0.5% -o ANIRIDIC CYNO 280 70 105 140 210 DAYS Fig. 1. Treatment protocols. Control eyes (110 R and 225 L) received same volume of diluent, containing NaCl in place of PI, as fellow experimental eyes. Cynomolgi (CYNO) 110 and 225 received virtually all treatments while fully conscious; cynomolgus 280 received alternate treatments under CI-744 anesthesia for the first 3 months. Aniridic, Iris totally removed8 previously; R, right eye; L, left eye; j, slit-lamp examination; P, posterior subcapsular lens opacities; A, anterior subcapsular opacities; V, lens vacuoles; ±, questionable lens opacities; C, clear lens; f, procedure or event other than slit-lamp examination (refraction not indicated); Eu enucleation following death by intracardiac pentobarbital; E2, enucleation in vivo under pentobarbital anesthesia. ciliary muscle.2 4 We report here another sodium phosphate, mannitol, and potassium ace- possible reason for loss of the IOP-lowering tate necessary to give concentrations equal to effect of ChE inhibitor treatment: ChE those in the corresponding PI solution. The os- inhibitor-induced structural alterations in the molality of the diluent was adjusted to approxi- anterior chamber angle. mate that of the corresponding PI solution by add- ing sodium chloride (1.8 or 9.0 mg/ml). The 0.5% Materials and methods PI solution had pH = 6.39 and osmolality = 435 Animals. Four adolescent or young adult cyno- mOsm; the corresponding diluent had pH = 6.30 molgus monkeys (Macaca fascicularis), weighing and osmolality = 425 mOsm. The 2.5% PI so- 1.8 to 2.4 kg, were studied. lution had pH = 6.97 and osmolality = 1900 Drugs. Ophthalmic PI was purchased com- mOsm; the corresponding diluent had pH = 6.91 mercially. To the drug powder was added the ac- and osmolality = 1820 mOsm. companying diluent to yield either a 0.5% or a Topical drug treatment. The eyes were treated 2.5% solution of echothiophate iodide (PI). Dilu- topically twice daily on weekdays (7:15 to 7:45 ent was made by adding to distilled water the A.M. and 4:15 to 4:45 P.M.) and once daily on quantities of boric acid, chlorobutanol, dibasic weekends (9:00 to 9:30 A.M.) with either PI or Downloaded from iovs.arvojournals.org on 09/26/2021 Invest. Ophthalmol. Visual Set. 920 Liitjen-Drecoll and Kaufman September 1979 ¥ K . Fig, 2. For legend see facing page. Downloaded from iovs.arvojournals.org on 09/26/2021 Volume 18 Number 9 Echothiophate-induced angle changes 921 diluent. The conscious animal was removed from treated with 1% periodic acid for 5 min to demon- its cage and restrained supine by a gloved assis- strate glycogen particles.10 tant. The upper lid was retracted digitally, and Results with a specially prepared microdropper, a 2.5 /xl drop of drug solution was applied to the central The morphological appearances of the PI cornea every 20 to 30 sec until the desired drug and diluent-treated eyes were compared with dose had been administered. Blinking was pre- each other and with the appearances of a large vented between drops and for 20 to 30 sec after number of non-PI-, non-fZi/«en£-treated the last drop. The lids were then wiped dry and cynomolgus eyes.11"15 Total iridectomy8 itself the animal returned to its cage. Treatments under caused no abnormalities visible by LM or general anesthesia were given in a similar manner, TEM in the ciliary muscle, trabecular but without assistance. Separate droppers were meshwork, or Schlemm's canal.8' 15 used for each of the four drug solutions. PI-treated eyes Slit-lamp examination. This was performed pe- Trabecular meshwork and Schlemm's canal riodically on the anesthetized monkey.5'6 Anesthesia. General anesthesia for topical 54 DAYS PI. The cribriform meshwork adja- treatments and slit-lamp examination was by in- cent to Schlemm's canal was thicker and tramuscular CI-744 (Tilazol; Parke-Davis), 5 to 10 more dense than normal (Fig. 2, B). The mg/kg.7 cribriform endothelial cells were enlarged Fig. 1 gives additional details of treatment and and exhibited enlarged nuclei, prominent enucleation. Treatment was started with smaller nucleoli, and large amounts of rough surfaced doses (same solutions, fewer drops), and the dos- endoplasmic reticulum. Beneath the inner age was gradually increased over several weeks to wall endothelium and within the cribriform 2 minimize the risk of systemic toxicity. meshwork there was more fine fibrillar ma- Tissue processing terial than normal (Fig. 3, B). In the Cynomolgus 275. Immediately following enu- corneoscleral and uveal meshwork, the tra- cleation, postequatorial scleral windows were cut, and the eye was immersed in phosphate-buflfered becular endothelial cells were also activated. (pH 7.2) 2.5% glutaraldehyde for 1 hr. The eye 138 AND 155 DAYS PI. The changes were in was then opened equatorially, the posterior half general similar to those seen after 54 days but discarded, and the anterior half cut into small were much more pronounced. In some re- sagittal wedges. The wedges were processed for gions there was so much fine fibrillar material light microscopy (LM) and transmission electron that the inner canal wall was separated from 9 microscopy (TEM). the first subendothelial cell layer (Figs. 2, C, Cynomolgi 110, 225, and 280. Immediately fol- and 3, C). In the inner portion of the lowing enucleation, the eye was opened equato- corneoscleral meshwork and in the uveal rially, and the posterior half discarded. Under an meshwork, some of the trabecular endothe- operating microscope, the zonule was cut all lial cells were degenerating (evidenced by around with a fine Vannas scissors, with care being taken not to touch the lens or ciliary processes. swollen mitochondria and vacuolization The lens was lifted free by a stainless steel ring and within the cytoplasm), and in some places a glass rod and processed for other studies. Small they were separated from the trabecular sagittal wedges of the anterior ocular segment beams. However, in the subopercular12 re- were then cut and processed for LM and TEM.9 gion of the anterior part of the meshwork Some ultrathin sections from each eye were there were clusters of activated cells, perhaps Fig. 2. Trabecular meshwork and Schlemm's canal. A, Monkey 225 R, 54 days diluent.
Recommended publications
  • Supplementary Information
    Supplementary Information Network-based Drug Repurposing for Novel Coronavirus 2019-nCoV Yadi Zhou1,#, Yuan Hou1,#, Jiayu Shen1, Yin Huang1, William Martin1, Feixiong Cheng1-3,* 1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA 2Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA 3Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA #Equal contribution *Correspondence to: Feixiong Cheng, PhD Lerner Research Institute Cleveland Clinic Tel: +1-216-444-7654; Fax: +1-216-636-0009 Email: chengf@ccf.org Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. Supplementary Table S2. Protein sequence identities across 5 protein regions in 15 coronaviruses. Supplementary Table S3. HCoV-associated host proteins with references. Supplementary Table S4. Repurposable drugs predicted by network-based approaches. Supplementary Table S5. Network proximity results for 2,938 drugs against pan-human coronavirus (CoV) and individual CoVs. Supplementary Table S6. Network-predicted drug combinations for all the drug pairs from the top 16 high-confidence repurposable drugs. 1 Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. GenBank ID Coronavirus Identity % Host Location discovered MN908947 2019-nCoV[Wuhan-Hu-1] 100 Human China MN938384 2019-nCoV[HKU-SZ-002a] 99.99 Human China MN975262
    [Show full text]
  • Drug Class Review Ophthalmic Cholinergic Agonists
    Drug Class Review Ophthalmic Cholinergic Agonists 52:40.20 Miotics Acetylcholine (Miochol-E) Carbachol (Isopto Carbachol; Miostat) Pilocarpine (Isopto Carpine; Pilopine HS) Final Report November 2015 Review prepared by: Melissa Archer, PharmD, Clinical Pharmacist Carin Steinvoort, PharmD, Clinical Pharmacist Gary Oderda, PharmD, MPH, Professor University of Utah College of Pharmacy Copyright © 2015 by University of Utah College of Pharmacy Salt Lake City, Utah. All rights reserved. Table of Contents Executive Summary ......................................................................................................................... 3 Introduction .................................................................................................................................... 4 Table 1. Glaucoma Therapies ................................................................................................. 5 Table 2. Summary of Agents .................................................................................................. 6 Disease Overview ........................................................................................................................ 8 Table 3. Summary of Current Glaucoma Clinical Practice Guidelines ................................... 9 Pharmacology ............................................................................................................................... 10 Methods .......................................................................................................................................
    [Show full text]
  • Demecarium Bromide/Homatropine 1881
    Demecarium Bromide/Homatropine 1881 Dyflos (BAN) junctival injection of pralidoxime has been used to reverse severe ocular adverse effects. Supportive treatment, including assisted DFP; Difluorophate; Di-isopropyl Fluorophosphate; Di-isopro- ventilation, should be given as necessary. CH3 pylfluorophosphonate; Fluostigmine; Isoflurofato; Isoflurophate. Di-isopropyl phosphorofluoridate. To prevent or reduce development of iris cysts in patients receiv- N ing ecothiopate eye drops, phenylephrine eye drops may be giv- C6H14FO3P = 184.1. en simultaneously. CAS — 55-91-4. ATC — S01EB07. Precautions ATC Vet — QS01EB07. As for Neostigmine, p.632. For precautions of miotics, see also OH under Pilocarpine, p.1885. In general, as with other long-acting anticholinesterases, ecothiopate should be used only where ther- O apy with other drugs has proved ineffective. Ecothiopate iodide CH3 should not be used in patients with iodine hypersensitivity. O O H3C O Interactions P CH3 As for Neostigmine, p.632. The possibility of an interaction re- O F mains for a considerable time after stopping long-acting anti- Homatropine Hydrobromide (BANM) CH3 cholinesterases such as ecothiopate. Homatr. Hydrobrom.; Homatropiinihydrobromidi; Homatropi- Pharmacopoeias. In US. Uses and Administration na, hidrobromuro de; Homatropine, bromhydrate d’; Homatro- USP 31 (Isoflurophate). A clear, colourless, or faintly yellow liq- Ecothiopate is an irreversible inhibitor of cholinesterase; its ac- pin-hidrobromid; Homatropinhydrobromid; Homatropin-hydro- uid. Specific gravity about 1.05. Sparingly soluble in water; sol- tions are similar to those of neostigmine (p.632) but much more bromid; Homatropini hydrobromidum; Homatropinium Bro- uble in alcohol and in vegetable oils. It is decomposed by mois- prolonged. Its miotic action begins within 1 hour of its applica- mide; Homatropino hidrobromidas; Homatropinum Bromatum; ture with the evolution of hydrogen fluoride.
    [Show full text]
  • Pharmacology of Ophthalmologically Important Drugs James L
    Henry Ford Hospital Medical Journal Volume 13 | Number 2 Article 8 6-1965 Pharmacology Of Ophthalmologically Important Drugs James L. Tucker Follow this and additional works at: https://scholarlycommons.henryford.com/hfhmedjournal Part of the Chemicals and Drugs Commons, Life Sciences Commons, Medical Specialties Commons, and the Public Health Commons Recommended Citation Tucker, James L. (1965) "Pharmacology Of Ophthalmologically Important Drugs," Henry Ford Hospital Medical Bulletin : Vol. 13 : No. 2 , 191-222. Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol13/iss2/8 This Article is brought to you for free and open access by Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Henry Ford Hospital Medical Journal by an authorized editor of Henry Ford Health System Scholarly Commons. For more information, please contact acabrer4@hfhs.org. Henry Ford Hosp. Med. Bull. Vol. 13, June, 1965 PHARMACOLOGY OF OPHTHALMOLOGICALLY IMPORTANT DRUGS JAMES L. TUCKER, JR., M.D. DRUG THERAPY IN ophthalmology, like many specialties in medicine, encompasses the entire spectrum of pharmacology. This is true for any specialty that routinely involves the care of young and old patients, surgical and non-surgical problems, local eye disease (topical or subconjunctival drug administration), and systemic disease which must be treated in order to "cure" the "local" manifestations which frequently present in the eyes (uveitis, optic neurhis, etc.). Few authors (see bibliography) have attempted an introduction to drug therapy oriented specifically for the ophthalmologist. The new resident in ophthalmology often has a vague concept of the importance of this subject, and with that in mind this paper was prepared.
    [Show full text]
  • 2021 Formulary List of Covered Prescription Drugs
    2021 Formulary List of covered prescription drugs This drug list applies to all Individual HMO products and the following Small Group HMO products: Sharp Platinum 90 Performance HMO, Sharp Platinum 90 Performance HMO AI-AN, Sharp Platinum 90 Premier HMO, Sharp Platinum 90 Premier HMO AI-AN, Sharp Gold 80 Performance HMO, Sharp Gold 80 Performance HMO AI-AN, Sharp Gold 80 Premier HMO, Sharp Gold 80 Premier HMO AI-AN, Sharp Silver 70 Performance HMO, Sharp Silver 70 Performance HMO AI-AN, Sharp Silver 70 Premier HMO, Sharp Silver 70 Premier HMO AI-AN, Sharp Silver 73 Performance HMO, Sharp Silver 73 Premier HMO, Sharp Silver 87 Performance HMO, Sharp Silver 87 Premier HMO, Sharp Silver 94 Performance HMO, Sharp Silver 94 Premier HMO, Sharp Bronze 60 Performance HMO, Sharp Bronze 60 Performance HMO AI-AN, Sharp Bronze 60 Premier HDHP HMO, Sharp Bronze 60 Premier HDHP HMO AI-AN, Sharp Minimum Coverage Performance HMO, Sharp $0 Cost Share Performance HMO AI-AN, Sharp $0 Cost Share Premier HMO AI-AN, Sharp Silver 70 Off Exchange Performance HMO, Sharp Silver 70 Off Exchange Premier HMO, Sharp Performance Platinum 90 HMO 0/15 + Child Dental, Sharp Premier Platinum 90 HMO 0/20 + Child Dental, Sharp Performance Gold 80 HMO 350 /25 + Child Dental, Sharp Premier Gold 80 HMO 250/35 + Child Dental, Sharp Performance Silver 70 HMO 2250/50 + Child Dental, Sharp Premier Silver 70 HMO 2250/55 + Child Dental, Sharp Premier Silver 70 HDHP HMO 2500/20% + Child Dental, Sharp Performance Bronze 60 HMO 6300/65 + Child Dental, Sharp Premier Bronze 60 HDHP HMO
    [Show full text]
  • View Is Primarily on Addressing the Issues of Non-Permanently Charged Reactivators and the Development of Treatments for Aged Ache
    Design, Synthesis, and Evaluation of Therapeutics for the Treatment of Organophosphorus Poisoning by Nerve Agents and Pesticides Dissertation Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Andrew Joseph Franjesevic Graduate Program in Chemistry The Ohio State University 2019 Dissertation Committee Professor Christopher M. Hadad, Advisor Professor Thomas J. Magliery Professor David Nagib Professor Jonathan R. Parquette Copyrighted by Andrew Joseph Franjesevic 2019 2 Abstract Organophosphorus (OP) compounds, both pesticides and nerve agents, are some of the most lethal compounds known to man. Although highly regulated for both military and agricultural use in Western societies, these compounds have been implicated in hundreds of thousands of deaths annually, whether by accidental or intentional exposure through agricultural or terrorist uses. OP compounds inhibit the function of the enzyme acetylcholinesterase (AChE), and AChE is responsible for the hydrolysis of the neurotransmitter acetylcholine (ACh), and it is extremely well evolved for the task. Inhibition of AChE rapidly leads to accumulation of ACh in the synaptic junctions, resulting in a cholinergic crisis which, without intervention, leads to death. Approximately 70-80 years of research in the development, treatment, and understanding of OP compounds has resulted in only a handful of effective (and approved) therapeutics for the treatment of OP exposure. The search for more effective therapeutics is limited by at least three major problems: (1) there are no broad scope reactivators of OP-inhibited AChE; (2) current therapeutics are permanently positively charged and cannot cross the blood-brain barrier efficiently; and (3) current therapeutics are ineffective at treating the aged, or dealkylated, form of AChE that forms following inhibition of of AChE by various OPs.
    [Show full text]
  • Medi-Cal Formulary
    2021年加州Medi-Cal管理式護 理承付藥物手冊 (承保藥物清單) 請閱讀:本文件包含當您參與由KAISER PERMANENTE所提供的MEDI-CAL管理式保健計劃 時,屬於計劃承保範圍的藥物相關資訊。 本承付處方藥物手冊是於 09/01/2021 更新且自 September 7, 2021, 起生效。本承付藥物 手冊文件可能會有變更且內容可能會隨您的保健計劃而異。如需最新資訊或對哪份承付藥 物手冊適用於您的計劃有疑問,請瀏覽kp.org/formulary(英文)或致電會員服務聯絡中心 ,服務時間為每週七天,每天24小時(假日休息)。英文1-800-464-4000(並提供超過 150種語言的服務)、西班牙文1-800-788-0616、華語方言1-800-757-7585以及供失聰或 聽障人士使用的聽障及語障電話專線711。 什麼是Kaiser Permanente《加州Medi-Cal管理式護理承付藥物手冊》? 《加州Medi-Cal管理式護理承付藥物手冊》(California Medi-Cal Managed Care Formulary) 是一份承保藥物清單,這些藥物是由Kaiser Permanente醫生和藥劑師所組成的藥事委員會 所挑選。藥事委員會將會定期舉行會議,以替會員評估和選擇安全有效的藥物。本承付藥物 手冊符合州法律的規定、條例以及Medi-Cal管理式保健計劃的準則。 哪些藥物屬於承保範圍? Kaiser Permanente承保列於《加州Medi-Cal管理式護理承付藥物手冊》的品牌藥、非品牌藥及 專科藥物, 但條件是該藥物是醫療上必要的藥物、處方是在Kaiser Permanente或附屬藥房配領且有遵守其 他保險規定。 如果醫生開立《加州Medi-Cal管理式護理承付藥物手冊》中的藥物給您,該藥物將會根據 您的藥物理賠條款獲得承保。 獲得承付藥物手冊例外處理 未列於承付藥物手冊中的藥物稱為非承付藥物手冊藥物。當Kaiser Permanente醫生認定非承付 藥物手冊藥物是醫療上適當且必要的藥物,該藥物將會根據您的理賠條款獲得承保(如果您享 有處方藥理賠)。如果您未享有特定類型的處方藥(如性功能障礙及不孕)保險,您將需為該 藥物支付零售價的全額。 您可向醫生洽詢是否需要進行承付藥物手冊例外處理。您和醫生最能確定您的藥物需求。 Kaiser Permanente 2021 年《加州Medi-Cal管理式護理承付藥物手冊》 • 第 1 of 144 您也可與會員服務部聯絡,服務時間為每週7天,每天24小時。 如果您想使用醫生認定為非醫療上必 要的非承付藥物手冊藥物,您可能必須向會員服務部提出抱怨。 承付藥物手冊中的承保藥物有任何限制嗎? 有些承保藥物可能有其他承保範圍規定或限制,如藥量限制。Kaiser Permanente可能會將特 定藥物的發配藥量限制在一定天數的藥量。此外,當某項藥物在全國發生短缺時,我們也可能 會限制該藥物的發配藥量。 什麼是品牌藥? 品牌藥通常是由最初研發藥物的製藥公司所製造和販售。當品牌藥的專利到期之後,其他製藥 公司便可使用相同的活性成分並以較低的價格製造和販售經由食品及藥物管理署 (Food and Drug Administration, FDA) 核准的非品牌藥版本。 什麼是非品牌藥? 非品牌藥是經由FDA核准且與品牌藥具備相同活性成分的藥物。非品牌藥的費用通常低於品 牌藥。 什麼是專科藥物? 專科藥物是非常高價位、經由FDA核准且列於承付藥物手冊中,用於治療如風濕性關節炎、 多發性硬化症或癌症等複雜慢性病的藥物。 哪些藥物有資格透過郵購藥房郵寄? 大多數藥物皆可透過郵購藥房郵寄。某些藥物(如非常高價位或需要特殊處理的藥物)可能
    [Show full text]
  • Wo 2008/127291 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 23 October 2008 (23.10.2008) WO 2008/127291 A2 (51) International Patent Classification: Jeffrey, J. [US/US]; 106 Glenview Drive, Los Alamos, GOlN 33/53 (2006.01) GOlN 33/68 (2006.01) NM 87544 (US). HARRIS, Michael, N. [US/US]; 295 GOlN 21/76 (2006.01) GOlN 23/223 (2006.01) Kilby Avenue, Los Alamos, NM 87544 (US). BURRELL, Anthony, K. [NZ/US]; 2431 Canyon Glen, Los Alamos, (21) International Application Number: NM 87544 (US). PCT/US2007/021888 (74) Agents: COTTRELL, Bruce, H. et al.; Los Alamos (22) International Filing Date: 10 October 2007 (10.10.2007) National Laboratory, LGTP, MS A187, Los Alamos, NM 87545 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY,BZ, CA, CH, (30) Priority Data: CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, 60/850,594 10 October 2006 (10.10.2006) US ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (71) Applicants (for all designated States except US): LOS LR, LS, LT, LU, LY,MA, MD, ME, MG, MK, MN, MW, ALAMOS NATIONAL SECURITY,LLC [US/US]; Los MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, Alamos National Laboratory, Lc/ip, Ms A187, Los Alamos, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, NM 87545 (US).
    [Show full text]
  • FDA Listing of Established Pharmacologic Class Text Phrases January 2021
    FDA Listing of Established Pharmacologic Class Text Phrases January 2021 FDA EPC Text Phrase PLR regulations require that the following statement is included in the Highlights Indications and Usage heading if a drug is a member of an EPC [see 21 CFR 201.57(a)(6)]: “(Drug) is a (FDA EPC Text Phrase) indicated for Active Moiety Name [indication(s)].” For each listed active moiety, the associated FDA EPC text phrase is included in this document. For more information about how FDA determines the EPC Text Phrase, see the 2009 "Determining EPC for Use in the Highlights" guidance and 2013 "Determining EPC for Use in the Highlights" MAPP 7400.13.
    [Show full text]
  • Nerve Agents Countermeasures–Where To
    safe Bio ty Kamil Kuca et al., Biosafety 2013, 2:2 Biosafety DOI: 10.4172/2167-0331.1000e134 ISSN: 2167-0331 Editorial Open Access Nerve Agents Countermeasures–Where to Go? Kamil Kuca1*,3, Daniel Jun1,2 and Kamil Musilek1,3 1Department of Military Health Sciences, University of Defence, Hradec Kralove, Czech Republic 2University Hospital, Hradec Kralove, Czech Republic 3University of Hradec Kralove, Department of Science, Department of Chemistry, Hradec Kralove, Czech Republic Organophosphorus (OP) acetylcholinesterase (AChE; EC The signs, symptoms and the severity of NA poisoning are also 3.1.1.7) inhibitors are widely utilized in agriculture as pesticides (e.g. depending on the absorbed amount, which entered the body. At chlorpyrifos, parathion, diazinon) and in industry as softening agents, muscarinic receptors (parasympathetic effects), they cause constricted additives or lubricants. They are also used in medicine as ophthalmic pupils (miosis), glandular hypersecretion (salivary, bronchial, agents (echothiophate, isoflurophate) or they were tested for their lacrimal, bronchoconstriction, vomiting, diarrhoea, urinary and potential benefit as drugs for Alzheimer’s disease (e.g. trichlorfon). faecal incontinence, bradycardia). At nicotinic receptors (motor and Some of most toxic OP inhibitors were developed before and during the post-ganglionic sympathetic effects) they cause sweating of the skin. World War II as chemical warfare agents and were called Nerve Agents On the skeletal muscle, they cause initial defasciculation followed by (NA) [1]. Among them, sarin is probably the most known member of weakness and flaccid paralysis. At central nervous system, they produce this family, because of its misuse by terrorists in Japan (1995). At that irritability, giddiness, fatigue, emotional labiality, lethargy, amnesia, time, several kilograms of this agent were spread in Tokyo subway by a ataxia, fasciculation seizures, coma and central respiratory depression Japanese religious cult AumShinrikyo.
    [Show full text]
  • Bacterial Expression of Human Butyrylcholinesterase As a Tool for Nerve Agent Bioscavengers Development
    molecules Article Bacterial Expression of Human Butyrylcholinesterase as a Tool for Nerve Agent Bioscavengers Development Xavier Brazzolotto 1,* ID , Alexandre Igert 1, Virginia Guillon 1, Gianluca Santoni 2 ID and Florian Nachon 1 1 Institut de Recherche Biomédicale des Armées, Département de Toxicologie et Risques Chimiques, 1 Place Général Valérie André, 91223 Brétigny-sur-Orge, France; alexandre.igert@chemdef.fr (A.I.); virginia.guillon@chemdef.fr (V.G.); florian@nachon.net (F.N.) 2 European Synchrotron Radiation Facility, 71 Avenue des Martyrs, 38043 Grenoble CEDEX 9, France; gianluca.santoni@esrf.fr * Correspondence: xavier@brazzolotto.net; Tel.: +33-178-65-1400 Received: 11 October 2017; Accepted: 23 October 2017; Published: 27 October 2017 Abstract: Human butyrylcholinesterase is a performant stoichiometric bioscavenger of organophosphorous nerve agents. It is either isolated from outdated plasma or functionally expressed in eukaryotic systems. Here, we report the production of active human butyrylcholinesterase in a prokaryotic system after optimization of the primary sequence through the Protein Repair One Stop Shop process, a structure- and sequence-based algorithm for soluble bacterial expression of difficult eukaryotic proteins. The mutant enzyme was purified to homogeneity. Its kinetic parameters with substrate are similar to the endogenous human butyrylcholinesterase or recombinants produced in eukaryotic systems. The isolated protein was prone to crystallize and its 2.5-Å X-ray structure revealed an active site gorge region identical to that of previously solved structures. The advantages of this alternate expression system, particularly for the generation of butyrylcholinesterase variants with nerve agent hydrolysis activity, are discussed. Keywords: butyrylcholinesterase; prokaryotic expression; PROSS; SEC-MALS; differential scanning fluorimetry; 3D structure 1.
    [Show full text]
  • What Killed Kim Jong-Nam? Was It the Agent Vx?
    Mil. Med. Sci. Lett. (Voj. Zdrav. Listy) 2017, vol. 86(2), p. 86-89 ISSN 0372-7025 DOI: 10.31482/mmsl.2017.013 LETTER TO THE EDITOR WHAT KILLED KIM JONG-NAM? WAS IT THE AGENT VX? INTRODUCTION Kim Jong-nam (10 May 1971 – 13 February 2017) was the eldest son of Kim Jong-il, leader of North Korea, and the estranged half-brother of North Korean dictator Kim Jong-un. From roughly 1994 to 2001, he was consid - ered the heir to his father [1]. Following a series of actions showing dissent to the North Korean regime, including a failed attempt to visit Tokyo Disneyland in May 2001 by entering Japan with a false passport, he was thought to have fallen out of favour with his father. On 13 February 2017, Kim was allegedly murdered by two women who fled after the crime [2]. The murder was commited in Malaysia during his return trip to Macau, at the low-cost carrier terminal of the Kuala Lumpur International Airport [3]. Initial reports suggest that Kim Jong-nam was mur - dered by VX, a type of agent used in chemical warfare [4]. Toxicological tests showed the presence of VX in Kim's eyes and face [5]. What is the agent VX and could this toxic substance cause the death of Kim? What is it VX? The VX is very toxic organophosphate (CAS Number 50782-69-9, O-ethyl-S-2-diisopropylaminoethyl methylphosphonothiolate) and extremely active cholinesterase inhibitor. At room temperature it is odorless, colorless to straw-colored liquid with m.p.
    [Show full text]